{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-25-000133","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.474584+00:00","generated_at":"2026-05-16T21:23:10.326053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immuneering Q3: 86% 9-month OS in pancreatic cancer; raised $225M; cash into 2029","bullets":["Reported 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib + mGnP.","Raised $225M in financing ($175M public offering + $25M Sanofi placement + $25M private placement).","Cash and equivalents $227.6M as of Sep 30, 2025; cash runway extended into 2029.","Granted US composition of matter patent for atebimetinib expiring 2042, with potential term extension.","New case studies show complete response and conversion to curative-intent surgery with atebimetinib + FOLFIRINOX."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-25-000133","json":"https://secwatch.observer/filing/0001790340-25-000133.json","markdown":"https://secwatch.observer/filing/0001790340-25-000133.md","text":"https://secwatch.observer/filing/0001790340-25-000133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/0001790340-25-000133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000133/imrx-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:23:10.326053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}